Clinical Trial: BBV152/BBV154 Heterologus Prime-Boost Study
Study Status: Completed
Recruit Status: Completed
Condition: Corona Virus Infection
Study Type: Interventional
Official Title: Phase 2 Randomized, Multi-centric of Heterologus Prime-Boost Combination of SARS-CoV-2 Vaccines to Evaluate the Immunogenicity and Safety of BBV152 (COVAXIN®) With BBV154 (Adenoviral Intranasal COVID-
Brief Summary:
All participants will be assessed for immunogenicity and safety endpoints and provide a blood sample before the administration of the first dose of IP. Blood samples will be collected on days 0, 9 (Groups 1, 3 and 4), 28,37 (Groups 2 and 4), 56, 90 and 180 to assess the neutralizing antibody titer against the SARSCoV-2 virus. A subset of 160 Participants (40 participants from each group) will be assessed for immunogenicity analysis, among these subset 10mL of blood and 5mL of saliva will be collected on days 0, 9…
Read more